ATE323766T1 - Glykosylierte leptinzusammensetzungen und zugehörige verfahren - Google Patents
Glykosylierte leptinzusammensetzungen und zugehörige verfahrenInfo
- Publication number
- ATE323766T1 ATE323766T1 AT00911784T AT00911784T ATE323766T1 AT E323766 T1 ATE323766 T1 AT E323766T1 AT 00911784 T AT00911784 T AT 00911784T AT 00911784 T AT00911784 T AT 00911784T AT E323766 T1 ATE323766 T1 AT E323766T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- glycosylated
- compositions
- glycosylated leptin
- leptin
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical class O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 102000035122 glycosylated proteins Human genes 0.000 abstract 1
- 108091005608 glycosylated proteins Proteins 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24967599A | 1999-02-12 | 1999-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323766T1 true ATE323766T1 (de) | 2006-05-15 |
Family
ID=22944511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00911784T ATE323766T1 (de) | 1999-02-12 | 2000-02-11 | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1151102B1 (de) |
| JP (1) | JP4841037B2 (de) |
| AT (1) | ATE323766T1 (de) |
| AU (1) | AU781460B2 (de) |
| CA (1) | CA2359840C (de) |
| CY (1) | CY1107470T1 (de) |
| DE (1) | DE60027409T2 (de) |
| DK (1) | DK1151102T3 (de) |
| ES (1) | ES2257287T3 (de) |
| PT (1) | PT1151102E (de) |
| WO (1) | WO2000047741A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US20050065078A1 (en) * | 2001-08-29 | 2005-03-24 | Cawthorne Anthony Michael | Use of leptin for infant with low birth weight for prevention of obesity |
| AU2002359288B2 (en) * | 2001-10-22 | 2008-07-31 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| ES2333724T3 (es) | 2003-09-26 | 2010-02-26 | Merck Serono Sa | Secuencias lideres para uso en la produccion de proteinas. |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
| WO2008067599A1 (en) * | 2006-12-04 | 2008-06-12 | Apollo Life Sciences Limited | Isolated leptin and adiponectin molecules and chimeric molecules thereof |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| JP2009126856A (ja) * | 2007-11-28 | 2009-06-11 | Fancl Corp | 血中中性脂肪上昇抑制剤 |
| CA2725143A1 (en) | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| RS58010B1 (sr) | 2012-09-27 | 2019-02-28 | Childrens Medical Ct Corp | Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| EP3481413A4 (de) * | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | Fusionsprotein mit leptin und verfahren zur herstellung und verwendung davon |
| HUE063647T2 (hu) | 2016-09-12 | 2024-01-28 | Amryt Pharmaceuticals Inc | Eljárások anti-leptin semlegesítõ antitestek detektálására |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
| CN1057534C (zh) * | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| AU4766596A (en) * | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
| PT866720E (pt) * | 1995-11-22 | 2004-06-30 | Amgen Inc | Proteina ob para aumentar a massa do tecido mole |
| AU1406497A (en) * | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
| JPH09176198A (ja) * | 1995-12-28 | 1997-07-08 | Kikkoman Corp | 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ |
| EP0877627A1 (de) * | 1996-01-25 | 1998-11-18 | Eli Lilly And Company | Analoge verbindungen des obesitätsproteins und ihre zubereitungen |
| EP0827750A3 (de) * | 1996-08-23 | 2002-11-20 | Eli Lilly And Company | Formulierungen des Obesitäts-Proteins |
| WO1999023115A1 (en) * | 1997-10-31 | 1999-05-14 | Eli Lilly And Company | Glycosylated obesity protein analogs |
| JP4199421B2 (ja) * | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
| US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
-
2000
- 2000-02-11 AU AU33623/00A patent/AU781460B2/en not_active Ceased
- 2000-02-11 ES ES00911784T patent/ES2257287T3/es not_active Expired - Lifetime
- 2000-02-11 DK DK00911784T patent/DK1151102T3/da active
- 2000-02-11 WO PCT/US2000/003652 patent/WO2000047741A1/en not_active Ceased
- 2000-02-11 CA CA2359840A patent/CA2359840C/en not_active Expired - Fee Related
- 2000-02-11 AT AT00911784T patent/ATE323766T1/de active
- 2000-02-11 JP JP2000598639A patent/JP4841037B2/ja not_active Expired - Fee Related
- 2000-02-11 PT PT00911784T patent/PT1151102E/pt unknown
- 2000-02-11 EP EP00911784A patent/EP1151102B1/de not_active Expired - Lifetime
- 2000-02-11 DE DE60027409T patent/DE60027409T2/de not_active Expired - Lifetime
-
2006
- 2006-07-07 CY CY20061100939T patent/CY1107470T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1151102E (pt) | 2006-07-31 |
| CY1107470T1 (el) | 2012-12-19 |
| DK1151102T3 (da) | 2006-05-29 |
| JP4841037B2 (ja) | 2011-12-21 |
| EP1151102A1 (de) | 2001-11-07 |
| DE60027409D1 (de) | 2006-05-24 |
| WO2000047741A1 (en) | 2000-08-17 |
| AU781460B2 (en) | 2005-05-26 |
| AU3362300A (en) | 2000-08-29 |
| JP2002536018A (ja) | 2002-10-29 |
| EP1151102B1 (de) | 2006-04-19 |
| DE60027409T2 (de) | 2007-04-12 |
| CA2359840C (en) | 2012-10-23 |
| CA2359840A1 (en) | 2000-08-17 |
| ES2257287T3 (es) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE323766T1 (de) | Glykosylierte leptinzusammensetzungen und zugehörige verfahren | |
| AU2001254624A1 (en) | Human coagulation factor vii variants | |
| BRPI0410164A (pt) | composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano | |
| CY1112655T1 (el) | Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις | |
| YU48703A (sh) | Novi interferonu beta-slični molekuli | |
| HUP0001153A2 (hu) | Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| EP2330127A3 (de) | Kalikrein-hemmende Kunitzdomänenproteine und Nukleinsäuren, die diese codieren | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| WO2003059934A3 (en) | Albumin fusion proteins | |
| WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
| WO2002060955A3 (en) | Modified antibodies and methods of use | |
| DE60307701D1 (de) | Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen | |
| HUP0103758A2 (hu) | Neurotróf faktorok | |
| EP0797999A3 (de) | Fettleibigkeitprotein-Formulierungen | |
| FI20075338A7 (fi) | gp350/220:n ei silmukoivia muutoksia | |
| ES2168361T3 (es) | Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo. | |
| WO2003033658A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
| IL81221A0 (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them | |
| DK0877803T3 (da) | OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder | |
| CA2002833A1 (en) | Interferon-gamma binding proteins | |
| ATE233321T1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen | |
| WO2002046458A3 (en) | Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof | |
| ATE230027T1 (de) | Menschliche dnase i varianten | |
| UA81601C2 (ru) | Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки | |
| WO2002102849A3 (en) | Bcmp-101, a cancer associated protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1151102 Country of ref document: EP |